Abstract:INTRODUCTION:Multiple sclerosis (MS) has a high comorbidity burden. Despite known associations with adverse outcomes, a comprehensive evaluation of the specific associations between individual comorbidities and disability, treatment initiation, and mortality remains underexplored. This study aimed to review and summarize existing evidence on the association between comorbidities and these three MS outcomes. METHODS:A rapid review spanning the period from January 2002 to October 2023 was conducted following the Cochrane Rapid Review Methods Group recommendations. MEDLINE, Embase, and the grey literature were searched to identify studies examining the effects of comorbidities on disability, treatment initiation, and mortality among individuals with MS. Data extraction and risk of bias assessments were systematically performed, with the Newcastle-Ottawa scale and A MeaSurement Tool to Assess systematic Reviews (AMSTAR-2) criteria for observational studies and systematic reviews respectively. RESULTS:The review included 100 primary studies, encompassing 88 different comorbidities. Most study populations were between 60-80% female, with an average age of 30-45 years at study start. The majority of included studies were conducted in Europe, North America, and Asia (specifically the Middle East). Over half (66%) of specific comorbidity-outcome relationships were examined within a single study only, and just two studies examined treatment initiation as an outcome. Methods used to assess comorbidities and outcomes varied widely and included self-report measures, medical records and diagnostic codes, and standardized clinical assessments. Depression was consistently associated with greater disability (adjusted hazard ratio (aHR): 1.50-3.59) and mortality (aHR: 1.62-3.55). Epilepsy was similarly associated with increased disability (aOR: 1.13-1.77) and increased mortality (aHR: 2.23-3.85). Diabetes was generally associated with increased mortality (aHR: 1.39-1.47), but results for disability were inconsistent. Most other conditions were examined in one or two studies only or findings varied across studies, unable to collectively indicate a clear association. Although the anxiety-disability relationship was assessed by 24 studies, the findings varied in terms of the presence, direction, and strength of a possible association, requiring nuanced interpretation. CONCLUSIONS:This study identifies relationships between various comorbidities and three outcomes in MS, providing a foundation for future research and clinical guidelines. People with psychiatric, metabolic, and neurological conditions may be at a higher risk of MS disease progression and may therefore benefit from the targeted treatment of their comorbidities. Overall, comorbidities have varying associations with MS outcomes and individual associations require further exploration. However, there is evidence that some comorbidities indicate worse disability and higher mortality risk, and present barriers to initiating MS treatment, making the prevention and management of comorbidities an integral piece of MS patient care. PROTOCOL:The protocol for this rapid review was registered on PROSPERO (ID: CRD42023475565) and published on Protocol Exchange (https://doi.org/10.21203/rs.3.pex-2438/v1).

Comorbid onset of cardiovascular diagnosis and long-term confirmed disability progression in multiple sclerosis: A 15-year follow-up study

Concomitant autoimmunity and risk of multiple sclerosis disability worsening

Comorbidity and Disease Activity in Multiple Sclerosis

Contemporary study of multiple sclerosis disability in South East Wales

Long-term disability trajectories in multiple sclerosis: a group-based trajectory analysis of the AusLong cohort

[A role of cerebrovascular diseases in the progression of multiple sclerosis]

Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England

Impact of Clinical and Demographic Factors on Disease Progression

Socioeconomic Status and Disability Progression in Multiple Sclerosis

Disability accrual in primary and secondary progressive multiple sclerosis

Modelling Disease progression of Multiple Sclerosis in a South Wales Cohort

Immune-inflammatory, Metabolic and Hormonal Biomarkers Are Associated with the Clinical Forms and Disability Progression in Patients with Multiple Sclerosis: A Follow-Up Study.

Clinical characteristics and dynamics of disability progression in a cohort of patients with multiple sclerosis in Latvians

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

Dynamic disability measures decrease the clinico-radiological gap in people with severely affected multiple sclerosis

Comorbidities and Their Association with Outcomes in the Multiple Sclerosis Population: A Rapid Review.

Longitudinal relationships between disability and gait characteristics in people with MS

Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model

WED 167 Socioeconomic Status and Progression of Disability in Ms

The contributions of vascular comorbidities on self-reported functional issues in persons with multiple sclerosis

Carotid intima-media thickness and risk of atherosclerosis in multiple sclerosis: A cross-sectional study